UK GA. Action for Access: A report from Genetic Alliance UK for the All Party Parliamentary Group on Rare, Genetic and Undiagnosed Conditions. 2019.

Foster MW, Mulvihill JJ, Sharp RR. Evaluating the utility of personal genomic information. Genet Med. 2009;11:570–4.

Article  PubMed  Google Scholar 

Regier DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation of health and nonhealth outcomes from next-generation sequencing: approaches, challenges, and solutions. Value Health. 2018;21:1043–7.

Article  PubMed  Google Scholar 

Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions. Value in Health. 2018;21:1033–42.

Article  PubMed  PubMed Central  Google Scholar 

Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, Firth HV, Frazier T, Hansen RL, Prock L. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Sci 2019:1.

Kohler JN, Turbitt E, Biesecker BB. Personal utility in genomic testing: a systematic literature review. Eur J Hum Genet. 2017;25:662–8.

Article  PubMed  PubMed Central  Google Scholar 

Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20:1122–30.

Article  PubMed  Google Scholar 

Jayasinghe K, Stark Z, Kerr PG, Gaff C, Martyn M, Whitlam J, Creighton B, Donaldson E, Hunter M, Jarmolowicz A, et al. Clinical impact of genomic testing in patients with suspected monogenic kidney disease. Genet Sci. 2021;23:183–91.

Google Scholar 

Eratne D, Schneider A, Lynch E, Martyn M, Velakoulis D, Fahey M, Kwan P, Leventer R, Rafehi H, Chong B, et al. The clinical utility of exome sequencing and extended bioinformatic analyses in adolescents and adults with a broad range of neurological phenotypes: an Australian perspective. J Neurol Sci. 2021;420:117260.

Article  CAS  PubMed  Google Scholar 

Goranitis I, Best S, Christodoulou J, Boughtwood T, Stark Z. Preferences and values for rapid genomic testing in critically ill infants and children: a discrete choice experiment. Eur J Hum Genet 2021:1–9.

Goranitis I, Best S, Stark Z, Boughtwood T, Christodoulou J. The value of genomic sequencing in complex pediatric neurological disorders: a discrete choice experiment. Genet Med. 2021;23:155–62.

Article  PubMed  Google Scholar 

Marshall DA, MacDonald KV, Heidenreich S, Hartley T, Bernier FP, Gillespie MK, McInnes B, Innes AM, Armour CM, Boycott KM. The value of diagnostic testing for parents of children with rare genetic diseases. Genet Med. 2019;21:2798–806.

Article  PubMed  Google Scholar 

Pearce C, Goettke E, Hallowell N, McCormack P, Flinter F, McKevitt C. Delivering genomic medicine in the United Kingdom National Health Service: a systematic review and narrative synthesis. Genet Med. 2019;21:2667–75.

Article  PubMed  Google Scholar 

Faulkner E, Holtorf A-P, Walton S, Liu CY, Lin H, Biltaj E, Brixner D, Barr C, Oberg J, Shandhu G, et al. Being Precise about Precision Medicine: what should Value Frameworks incorporate to address Precision Medicine? A report of the Personalized Precision Medicine Special Interest Group. Value in Health. 2020;23:529–39.

Article  PubMed  Google Scholar 

National Institute of Health and Care Excellence. Guide to the methods of technology appraisal. London: National Institute of Health and Care Excellence; 2013.

Google Scholar 

Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Department of Health and Ageing; 2016.

Google Scholar 

Canadian Agency for Drugs and Technology in Health. Guidelines for the economic evaluation of health technologies: Canada – 4th Edition. Ottawa: CADTH; 2017.

Google Scholar 

Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, Present and Future. Appl Health Econ Health Policy. 2017;15:127–37.

Article  PubMed  PubMed Central  Google Scholar 

Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–92.

Article  PubMed  Google Scholar 

Whittal A, Meregaglia M, Nicod E. The Use of patient-reported outcome measures in Rare Diseases and implications for Health Technology Assessment. The Patient - Patient-Centered Outcomes Research. 2021;14:485–503.

Article  PubMed  Google Scholar 

Meregaglia M, Nicod E, Drummond M. The estimation of health state utility values in rare Diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review. Eur J Health Econ 2022.

Bharmal M, Nolte S, Henry-Szatkowski M, Hennessy M, Schlichting M. Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma. Health Qual Life Outcomes. 2020;18:145.

Article  PubMed  PubMed Central  Google Scholar 

Buchanan J, Wordsworth S. Evaluating the outcomes Associated with genomic sequencing: a Roadmap for Future Research. Pharmacoecon Open. 2019;3:129–32.

Article  PubMed  Google Scholar 

Johnston BC, Miller PA, Agarwal A, Mulla S, Khokhar R, De Oliveira K, Hitchcock CL, Sadeghirad B, Mohiuddin M, Sekercioglu N, et al. Limited responsiveness related to the minimal important difference of patient-reported outcomes in rare Diseases. J Clin Epidemiol. 2016;79:10–21.

Article  PubMed  Google Scholar 

Nicod E, Meregaglia M, Whittal A, Upadhyaya S, Facey K, Drummond M. Consideration of quality of life in the health technology assessments of rare Disease treatments. Eur J Health Econ. 2022;23:645–69.

Article  PubMed  Google Scholar 

Norris S, Belcher A, Howard K, Ward RL. Evaluating genetic and genomic tests for heritable conditions in Australia: lessons learnt from health technology assessments. J Community Genet 2021.

12th Joint Call for Proposals. by EuroQol Working Groups [https://euroqol.org/12th-joint-call-for-proposals-by-euroqol-working-groups-is-now-open].

Stark Z, Boughtwood T, Phillips P, Christodoulou J, Hansen DP, Braithwaite J, Newson AJ, Gaff CL, Sinclair AH, North KN. Australian Genomics: a Federated Model for Integrating Genomics into Healthcare. Am J Hum Genet. 2019;105:7–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Al-Janabi H, Mallett A, Quinlan C, Scheffer IE, Howell KB, Christodoulou J, Leventer RJ, Lockhart PJ, Stark Z, et al. Parental health spillover effects of paediatric rare genetic conditions. Qual Life Res. 2020;29:2445–54.

Article  PubMed  Google Scholar 

Ware J Jr., Kosinski M, Keller SD. A 12-Item short-form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–33.

Article  PubMed  Google Scholar 

Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42:851–9.

Article  PubMed  Google Scholar 

Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. SF-12v2™: How to score version 2 of the SF-12® health survey. 2002.

Brazier JE, Mulhern BJ, Bjorner JB, Gandek B, Rowen D, Alonso J, Vilagut G, Ware JE. Developing a New Version of the SF-6D health state classification system from the SF-36v2: SF-6Dv2. Med Care 2020, 58.

Mulhern B, Norman R, Brazier J. Valuing SF-6Dv2 in Australia using an International Protocol. PharmacoEconomics. 2021;39:1151–62.

Article  PubMed  Google Scholar 

SF-6D &. SF-6Dv2 - calculating QALYs from the SF-36, SF-12 and the standalone SF-6Dv2 [https://licensing.sheffield.ac.uk/product/SF-6D].

Taylor N, Best S, Martyn M, Long JC, North KN, Braithwaite J, Gaff C. A transformative translational change programme to introduce genomics into healthcare: a complexity and implementation science study protocol. BMJ Open. 2019;9:e024681.

Article  PubMed  PubMed Central  Google Scholar 

Jayasinghe K, Stark Z, Kerr PG, Gaff C, Martyn M, Whitlam J, Creighton B, Donaldson E, Hunter M, Jarmolowicz A, et al. Clinical impact of genomic testing in patients with suspected monogenic Kidney Disease. Genet Med. 2021;23:183–91.

Article  PubMed  Google Scholar 

Jayasinghe K, Stark Z, Patel C, Mallawaarachchi A, McCarthy H, Faull R, Chakera A, Sundaram M, Jose M, Kerr P, et al. Comprehensive evaluation of a prospective Australian patient cohort with suspected genetic Kidney Disease undergoing clinical genomic testing: a study protocol. BMJ Open. 2019;9:e029541.

Article  PubMed  PubMed Central  Google Scholar 

Norman R, Mulhern B, Lancsar E, et al. The Use of a discrete choice experiment including both duration and dead for the development of an EQ-5D-5L value set for Australia. PharmacoEconomics. 2023;41:427–438. https://doi.org/10.1007/s40273-023-01243-0.

Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27:7–22.

Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, et al. United States Valuation of EQ-5D-5L Health States using an International Protocol. Value Health. 2019;22:931–41.

Article  PubMed  Google Scholar 

Lovibond SH, Lovibond PF. Manual for the depression anxiety & stress scales. 2nd ed. Sydney: Psychology Foundation; 1995.

Google Scholar 

Salsman JM, Victorson D, Choi SW, Peterman AH, Heinemann AW, Nowinski C, Cella D. Development and validation of the positive affect and well-being scale for the neurology quality of life (Neuro-QOL) measurement system. Qual Life Res. 2013;22:2569–80.

Article  PubMed  Google Scholar 

Neuro-QoL Group.: Quality of Life in Neurological Disorders Scoring Manual 2015.

Catchpool M, Ramchand J, Martyn M, Hare DL, James PA, Trainer AH, Knight J, Goranitis I. A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. Genet Sci. 2019;21:2815–22.

Google Scholar 

Ramchand J, Wallis M, Macciocca I, Lynch E, Farouque O, Martyn M, Phelan D, Chong B, Lockwood S, Weintraub R, et al. Prospective evaluation of the utility of whole exome sequencing in dilated cardiomyopathy. J Am Heart Association. 2020;9:e013346.

Article  CAS  Google Scholar 

Richardson J, Iezzi A, Khan MA, Maxwell A. Validity and reliability of the Assessment of Quality of Life (AQoL)-8D Multi-attribute Utility Instrument. The Patient - Patient-Centered Outcomes Research. 2014;7:85–96.

Article  PubMed  Google Scholar 

Richardson J, Khan MA, Chen G, Iezzi A, Maxwell A. Population norms and Australian profile using the Assessment of Quality of Life (AQoL) 8D utility instrument. In Centre for Health Economics Research Paper. Melbourne; 2012.

Catchpool M, Ramchand J, Hare DL, Martyn M, Goranitis I. Mapping the Minnesota living with Heart Failure questionnaire (MLHFQ) onto the Assessment of Quality of Life 8D (AQoL-8D) utility scores. Qual Life Res. 2020;29:2815–22.

Article  PubMed  Google Scholar 

Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ. 1999;8:41–51.

Article  CAS  PubMed  Google S